Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ritlecitinib to Prevent Gluten-induced Celiac Enteropathy and Symptoms in Celiac Disease Patients in Remission
NCT05636293Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Mar 2023
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ritlecitinib tosilate in celiac disease, sponsored by Massachusetts General Hospital. Started Mar 2023; status: completed.
02
Drugs
ritlecitinib tosilate
03
Conditions
celiac disease
Beyond the preview
Go deeper on NCT05636293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05636293.